Vanguard Group’s Longboard Pharmaceuticals, Inc. Common Stock LBPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-2,033,068
| Closed | -$67.8M | – | 4392 |
|
|
2024
Q3 | $67.8M | Buy |
2,033,068
+107,921
| +6% | +$3.72M | ﹤0.01% | 2054 |
|
|
2024
Q2 | $52M | Buy |
1,925,147
+200,716
| +12% | +$3.96M | ﹤0.01% | 2127 |
|
|
2024
Q1 | $37.2M | Buy |
1,724,431
+937,998
| +119% | +$20.5M | ﹤0.01% | 2297 |
|
|
2023
Q4 | $4.74M | Buy |
786,433
+5,360
| +0.7% | +$26.7K | ﹤0.01% | 3309 |
|
|
2023
Q3 | $4.34M | Buy |
781,073
+113,874
| +17% | +$733K | ﹤0.01% | 3310 |
|
|
2023
Q2 | $4.9M | Buy |
667,199
+268,720
| +67% | +$2.03M | ﹤0.01% | 3312 |
|
|
2023
Q1 | $1.6M | Buy |
398,479
+91,896
| +30% | +$449K | ﹤0.01% | 3756 |
|
|
2022
Q4 | $999K | Buy |
306,583
+3,835
| +1% | +$15.4K | ﹤0.01% | 3915 |
|
|
2022
Q3 | $1.13M | Sell |
302,748
-1,001
| -0.3% | -$3.7K | ﹤0.01% | 3964 |
|
|
2022
Q2 | $938K | Hold |
303,749
| – | – | ﹤0.01% | 4110 |
|
|
2022
Q1 | $1.62M | Hold |
303,749
| – | – | ﹤0.01% | 4041 |
|
|
2021
Q4 | $1.48M | Buy |
303,749
+130,400
| +75% | +$887K | ﹤0.01% | 4145 |
|
|
2021
Q3 | $1.53M | Buy |
173,349
+7,804
| +5% | +$72K | ﹤0.01% | 4134 |
|
|
2021
Q2 | $1.51M | Buy |
165,545
+110,545
| +201% | +$1.1M | ﹤0.01% | 4048 |
|
|
2021
Q1 | $900K | Buy |
+55,000
| New | +$899K | ﹤0.01% | 4035 |
|
Vanguard Group's LBPH Position: Q4 2024 in Review
Vanguard Group sold out of Longboard Pharmaceuticals, Inc. Common Stock (LBPH) in Q4 2024, closing a stake of 2,033,068 shares — an estimated $67.8M sold.
Vanguard Group first reported a position in LBPH in Q1 2021 and held it in 15 quarters. The position peaked at $67.8M in Q3 2024. 0 funds tracked by Wall St. Rank hold LBPH as of Q4 2024.
- Vanguard Group reported no remaining Longboard Pharmaceuticals, Inc. Common Stock position as of Q4 2024 after selling out during the quarter.
- Vanguard Group sold 2,033,068 Longboard Pharmaceuticals, Inc. Common Stock shares in Q4 2024, an estimated $67.8M.
- Vanguard Group first reported a position in Longboard Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 15 quarters.
- Vanguard Group's Longboard Pharmaceuticals, Inc. Common Stock position peaked at $67.8M in Q3 2024.
- 0 funds tracked by Wall St. Rank held Longboard Pharmaceuticals, Inc. Common Stock as of Q4 2024.
Based on Vanguard Group's 13F filing for Q4 2024, filed 11 Feb 2025.